重组人p53腺病毒注射液联合化疗治疗喉癌  

Clinical trial of treatment of laryngeal cancer by recombinant adenovirus p53 combined with chemotherapy

作　　者：窦晓辉[1] 赵晓明[1] 王燕群[1] 曾亮[1] 汪志伟[1] 

机构地区：[1]珠海市人民医院耳鼻咽喉科

出　　处：《临床耳鼻咽喉头颈外科杂志》2007年第18期848-850,共3页Journal of Clinical Otorhinolaryngology Head And Neck Surgery

摘　　要：目的:观察重组人p53腺病毒注射液(rAd2p53)瘤内注射联合顺铂加紫杉醇方案化疗与单纯化疗对喉癌动物模型的治疗效果,试图为此方法的临床应用提供实验室依据。方法:利用喉癌Hep-2细胞系小鼠背部注射建立喉癌的荷瘤动物模型,实验组在荷瘤部位瘤内注射重组人p53腺病毒注射液并静脉注射顺铂加紫杉醇;对照组1单纯瘤内注射p53腺病毒注射液;对照组2单纯静脉注射顺铂加紫杉醇,观察肿瘤治疗前后瘤体大小变化。结果:基因联合化疗治疗组肿瘤生长明显受抑制,疗效显著优于单纯基因及单纯化疗组。结论:重组人p53腺病毒注射液(rAd2p53)联合顺铂加紫杉醇方案化疗可显著提高喉癌治疗效果。Objective：To evaluate the effectiveness of recombinant adenovirus p53 injection（rAd2p53）） combined with cisplain plus 5-fluorouracil regimen in treating laryngeal carcinoma. Method： Tumour animal models were established in the back of mice with Hep-2 cell line. Recombinant adenovirus p53 injection（rAd2p53） were transducted to tumor-bearing mouse by direct intratumoral injection combine with cisplain plus 5-fluorouracil ivgtt. The control group 1 was gived recombinant adenovirus p53 injection（rAd2p53） simplex. The control group 2 was administered with cisplain plus 5-fluorouraci ivgtt simplex. Then compare the diameters of pro-treatment with that of post-treatment and test group with controls. Result： Tumor growth was significantly inhibited following combined rAd2p53 gene therapy with cisplain plus 5-fluorouracil chemotherapy compared to single rAd2p53 gene therapy and cisplain plus 5-fluorouracil chemotherapy controls. Conclusion： Local injection of rAd2p53 combined with cisplain plus 5-fluorouracil chemotherapy is a promising treatment to laryngeal cancer.

关 键 词：喉肿瘤 化学疗法 基因疗法 p53 

分 类 号：R739.65[医药卫生—肿瘤]